. 2012 Oct 11;28(3):248–254. doi: 10.1007/s12291-012-0260-5

Table 1.

Demographic and clinical characteristics of controls, CAD and AMI patients

	Controls (n = 100)	CAD (n = 100)	AMI (n = 100)	p value
Age (years)**	52.1 ± 9.1	55.5 ± 11.7	55.4 ± 13.5	0.063^a
Male/Female (n)	90/10	92/8	88/12	0.641^b
BMI (kg/m²)**	24.3 ± 4.2	27.3 ± 3.8^*	24.4 ± 4.2^†	0.0001^a
SBP (mm Hg)**	122.1 ± 8.1	131.8 ± 15.0*	23.9 ± 2.3*^†	0.0001^a
DBP (mm Hg)**	80.9 ± 5.1	83.1 ± 6.9	70.5 ± 18.7*^†	0.0001^a
Alcohol consumers	8	22*	17*	0.022^b
Smokers	26	20	56*^†	0.0001^b
Hypertensives	11	59*	25*^†	0.0001^b
HDL-C, mg/dL**	50.18 ± 15.07	44.44 ± 18.50*	39.49 ± 9.94*	0.0001^a
LDL-C, mg/dL**	91.07 ± 24.96	91.31 ± 35.85	115.65 ± 41.40*^†	0.0001^a
TG, mg/dL**	131.74 ± 52.02	136.13 ± 54.51	151.21 ± 72.71	0.060^a
T-CHO, mg/dL**	156.57 ± 51.0	163.62 ± 56.64	172.38 ± 45.77	0.094^a
PONase activity ‡ (U/ml)	179.8 (53.3–355.0)	102.0 (21.0–307.5)*	23.26 (4.7–130.0)*^†	0.0001^b
PONase/HDL-C ratio ‡ (U/mg)	36.9 (8.2–82.0)	25.2 (5.7–69.7)*	6.3 (0.8–55.8)*^†	0.0001^b

** Values are mean ± SD

‡ Values are median (range)

* p < 0.05 versus Controls

^†p < 0.05 versus CAD

^aOne way Anova test

^bKruskal wallis test